| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 25, 2005
Accepted on December 20, 2005
Dipartimento di Scienze Cliniche e Dipartimento di Medicina Sperimentale e Patologia, Università di Roma ‘La Sapienza’, Rome, Italy; IRCCS-Casa Sollievo della Sofferenza Hospital, Unit of Endocrinology, and Division of Anatomic Pathology, S. Giovanni Rotondo, Foggia, Italy; Dipartimento di Biologia e Patologia Cellulare e Molecolare, University ‘Federico II’ c/o Istituto di Endocrinologia ed Oncologia Sperimentale CNR, Naples, Italy.; Dipartimento di Medicina Sperimentale e Clinica ‘Gaetano Salvatore’ and Dipartimento di Scienze Farmacobiologiche, University of Catanzaro ‘Magna Graecia’, Catanzaro, Italy
* To whom correspondence should be addressed. E-mail: sebastiano.filetti{at}uniroma1.it.
Context: RET mutation analysis provides useful information on the clinical outcome of medullary thyroid carcinomas (MTC) and the risk of disease in the family members.
Objective: To document genotype-phenotype relationships in an Italian family with a novel RET mutation.
Design/Setting: RET gene alterations were investigated in a patient with multifocal MTC and her relatives. The identified mutation was subjected to in vitro functional testing.
Patients: A female proband who developed MTC at age 60, her five children, and three grandchildren.
Main outcome measures: DNA extracted from the blood and the proband's tumor was analyzed for RET alterations. The transforming potential and mitogenic properties of the identified mutation were investigated.
Results: A novel heterozygous germline RET mutation at codon 777 (AAC 224 AGC, N 224 S) (RET/N777S) was identified in the proband and three of her relatives. Two of the latter presented thyroid nodules, but none had MTC or C cell hyperplasia. The proband's MTC was characterized by late onset and limited aggressiveness, with no evidence of regional lymph node or distant metastases ten years after total thyroidectomy. This phenotype is consistent with the RET/N777S mutant's low-grade transforming potential and limited activation of RET tyrosine kinase.
Conclusion: Our findings indicate that the newly identified RET/N777S mutation is a low-penetrant cause of MTC disease. This phenotype might be less aggressive than that associated with MEN2A of familial MTC, although close clinical follow-up of carriers is essential.
This article has been cited by other articles:
![]() |
J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |